Sustained expression of inflammatory monocytes and activated T cells in COVID-19 patients and recovered convalescent plasma donors

Ravinder Singh1 | Hamed Hemati1 | Meenu Bajpai2 | Pushpa Yadav1 | Ashish Maheshwari2 | Suresh Kumar3 | Sonal Agrawal1 | Jayesh Kumar Sevak1 | Mojahidul Islam1 | Jaswinder Singh Mars1 | Shiv K Sarin4 | Nirupama Trehanpati1

1Laboratory of Molecular Immunology, Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India
2Department of Transfusion Medicine, Institute of Liver and Biliary Sciences, New Delhi, India
3Department of Medicine, Lok Nayak Jai Prakash Hospital, New Delhi, India
4Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India

Correspondence
Nirupama Trehanpati, Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, D-1, Vasant Kunj, New Delhi 110070, India. Email: trehanpati@gmail.com, trehanpati@ilbs.in

Abstract
Introduction: Intense monocyte activation and infiltration into the target tissues are the main mechanisms of lung injury in severe acute respiratory syndrome coronavirus 2 infection. A reduction in the degree and nature of such cellular responses is expected following recovery. We aimed to investigate the immune responses in moderate coronavirus disease 2019 (COVID-19) patients and recovered patients.

Methods: Moderate COVID-19 patients (n = 34) at Lok Nayak Hospital, New Delhi, and COVID-19 recovered patients (n = 15) from the mild disease who were considered for convalescent plasma (COPLA) donation at the Institute of Liver and Biliary Sciences, New Delhi and healthy individuals (n = 10), were recruited. We have assessed 21 plasma cytokines using cytokine bead array, performed proteomics on serum proteins, and analyzed immune cells using a detailed multicolor flow cytometry.

Results: A significant increase in inflammatory markers such as macrophage inflammatory protein (MIP)1-α, monocyte chemotactic protein-1, macrophage migration inhibitory factor, vascular endothelial growth factor-A, and Leptin was observed in the moderate patients. Nonsurvivors additionally showed

Abbreviations: APRIL, A proliferation-inducing ligand; BAFFR, B-cell activating factor receptor; BMI, body mass index; CBC, complete blood count; COPD, chronic obstructive pulmonary disease; COPLA, convalescent plasma; DC, dendritic cells; ENA78, neutrophil-activating peptide; FiO2, fraction of inspired oxygen; HC, healthy controls; HIV, human immunodeficiency virus; IFN, interferon; IL, interleukins; IP-10, IFN-γ inducible protein 10; ITAC, interferon-inducible T-cell α chemoattractant; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; PaO2, partial pressure of oxygen; PBMC, peripheral blood mononuclear cells; PCR, polymerase chain reaction; RR, respiratory rate; SD, standard deviation; SOFA score, sequential organ failure assessment score; TGF-β, transforming growth factor b; Tregs, regulatory T cells; VEGF, vascular endothelial growth factor; WB, whole blood.

Ravinder Singha and Hamed Hemati have equal contribution in this manuscript.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
increased interleukin (IL)-6 levels. Consistently, the proteomics analysis showed the signatures of cytokine production and interferon-γ response, and increased level of acute-phase protein SAA1 in the serum of COVID-19 patients. Despite the sustained expression of MIPs, the recovered COPLA donors showed a surge in MCSF and IL-18 levels. Both the groups had increased CCR2, CX3CR1 positive monocytes, low CD8+ T cells, A proliferation-inducing ligand, and B-cell activating factor receptor+ B cells compared with healthy subjects.

**Conclusions:** Patients who have recovered and considered for COPLA donations still have compromised immunity with sustained expression of inflammatory monocytes and activated T cells.

**Keywords**
convalescent plasma, COVID-19, cytokines, IL-6, immune cells, MIP

## 1 | INTRODUCTION

In December 2019, a new member of the Coronavirus family emerged in Wuhan, China; later termed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing a respiratory illness.1-3 SARS-CoV-2 eventually spread across the globe causing over 147.7 million infections and more than 3.1 million deaths. In India, SARS-CoV-2 has infected around 17.5 million people and has claimed around 200 thousand lives (https://www.worldometers.info/coronavirus/accessed on 26/04/2021). The clinical manifestations of coronavirus disease 2019 (COVID-19) varied from a mild disease with fever, cough, and little or no pneumonia to a moderate disease which presented as dyspnoea, hypoxia, and pneumonia, to a critical disease characterized by systemic shock, respiratory and multiorgan failure.4

SARS-CoV-2 is transmitted through the respiratory route. The initial site of infection for the virus is the respiratory epithelium. After infecting the lung epithelium, the inflammation spills over into the circulation generating an immune response mediated by leukocytes and cellular mediators of innate immunity including monocytes, macrophages, and dendritic cells. Indeed, SARS-CoV-2 may infect the circulating monocytes and blood-derived macrophages.5 The infected monocytes differentiate into macrophages with a greater expression of chemokine receptors and traffic via chemoattractants to the target organ. Stimulation of these receptors induces the expression of proinflammatory cytokines. Most of the COVID-19 patients exhibit lymphopenia and pneumonia with higher levels of cytokines in the moderate disease indicating that the virus-induced exacerbated immune responses play a key role in the pathogenesis, morbidity, mortality and recovery in patients. Further, T cells activation and excessive elimination of regulatory T cells add to uncontrolled pathogenesis in COVID-19.6,7

Many clinical studies have observed benefits with, intravenous Remdesivir, a combination of Lopinavir and Ritonavir, and also with convalescent plasma therapy8-10 for treating COVID-19 patients. Convalescent plasma therapy is considered very beneficial initially and still being considered by many groups.11-13 However, still, there is a key question about durability and longevity of immunity in recovered patients. Therefore, our aim in this study was to analyse immune markers in COVID-19 patients with mild to moderate disease and in recovered patients who had recovered from the disease and considered for convalescent plasma donations.

Here we described a novel observation that increased activated monocytes, T cells, and low A proliferation-inducing ligand (APRIL) and B-cell activating factor receptor (BAFFR) expressing B cells are present in COVID-19 patients and also have sustained existence of these markers in convalescent plasma (COPLA) donors even after 3 weeks of recovery.

## 2 | MATERIALS AND METHODS

### 2.1 | Patients and subjects

We prospectively recruited SARS-CoV-2 positive patients ($n = 34$) by real-time PCR assay with mild to moderate symptoms in the first week of disease at the Department of Internal Medicine, Lok Nayak Hospital, a designated COVID-19 treatment center in New Delhi, India and
COVID-19 recovered patients (n = 15) who have recovered from the mild disease and considered for convalescent plasma donation after 3 weeks of their recovery, at Institute of Liver and Biliary Sciences (ILBS), New Delhi, India, from May to July 2020. The severity of disease was characterized by respiratory distress, respiratory rate (RR) ≥30/min, oxygen saturation level <93% in resting state, the partial pressure of oxygen (PaO₂)/oxygen concentration (fraction of inspired oxygen [FiO₂]) ≤300 mmHg, within 24–48 h (Table 1). Patients less than 18 years or more than 65 years of age, those with comorbid conditions (cardio-pulmonary disease, structural or valvular heart disease, coronary artery disease, chronic obstructive pulmonary disease, chronic liver disease, chronic kidney disease), patients presenting with multiorgan failure, pregnant females, individuals with HIV, viral hepatitis, cancer, morbid obesity with a body mass index (BMI) more than 35 kg/m², extremely moribund patients with an expected life expectancy of less than 24 h or failure to obtain informed consent were excluded from this study.

Recovered patients were symptom-free for 3 weeks and had a negative real-time PCR assay. To compare the intensity of immune markers, healthy subjects (n = 10) were enrolled in this study.

2.2 | Sample collection

Both nasopharyngeal and oropharyngeal swabs were taken in a 3 ml viral transport media. A total of 6–8 ml peripheral blood was collected in ethylenediaminetetraacetic acid coated vacutainers from COVID-19 patients at the time of admission and recovered patients after 14 days of their recovery at the time of convalescent plasma donations. Plasma was separated and stored at −80°C for further use.

2.3 | Reverse transcription-polymerase chain reaction (RT-PCR)

A volume of 200 µl of the sample was processed for viral nucleic acid extraction by Qia symphony DSP Virus/Pathogen mini kit (Qiagen GmbH) as per the

| TABLE 1 Baseline characteristics of COVID-19 patients, COPLA donors, and healthy subjects |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Baseline parameters | COVID-19 patients (n = 34) | COPLA donors (n = 15) | Healthy subjects (n = 10) |
| Mean age (year ± SD) | 48.21 ± 9.79 | 38.07 ± 7.7 | 48.14 ± 9.05 |
| Male (n, %) | 22 (75.86%) | 15 (100%) | 7 (74%) |
| Chest X-ray changes (n, %) | 25 (86.20) | – | – |
| BMI (mean and SD) | 26.31 ± 2.29 | 26.84 ± 2.63 | 26.28 ± 2.52 |
| Respiratory rate/min (mean and SD) | 34.5 ± 2.55 | 14.14 ± 2.53 | 14 ± 2.65 |
| PaO₂ (mmHg) | 61.76 ± 4.96 | – | – |
| O₂ Saturation (%) | 85.03 ± 4.03 | 99 ± 1 | 99 ± 1 |
| FiO₂ (mmHg) | 0.38 ± 0.04 | – | – |
| PaO₂/FiO₂ ratio | 162.92 ± 13.77 | – | – |
| Baseline neutrophils (N, median and range) | 3375 (2626, 6928) | 4328 (2789, 6100) | 4535 (3160, 6000) |
| Baseline lymphocytes (L, median and range) | 968 (758, 1874) | 2371 (1400–2600) | 2453 (1550, 2890) |
| N/L ratio | 3.8 (3.37, 4.67) | 1.81 (1.6, 2.0) | 1.67 (1.52, 1.84) |
| Platelet count (in lakhs) (cmm³) | 1.8 ± 1.20 | 1.6 ± 1.43 | 2.2 ± 2.42 |
| SOFA score | 7.44 ± 1.86 | – | – |
| Baseline Ct value of RT-PCR | 31.91 ± 3.44 | – | – |

Abbreviations: COVID-19, coronavirus disease 2019; COPLA, considered for convalescent plasma; FiO₂, fraction of inspired oxygen; PaO₂, partial pressure of oxygen; RT-PCR, reverse transcription-polymerase chain reaction; SOFA, sequential organ failure assessment.
manufacturer’s protocol. The extracted elutes of RNA was subjected to RT-PCR for the qualitative detection of both E as well as ORF 1ab (RdRP) genes of the SARS-CoV-2 virus using a commercial RT-PCR kit (nCoV RT–PCR; SD Biosensor) as per the kit literature. The sample was considered positive when fluorescence was seen in both the target genes E as well as RdRP up to a cycle threshold (Ct) value 36. Ct values were utilized as a marker to monitor the clinical progress of the patients. Two consecutive negative test results of real-time RT-PCR were performed 24 h apart, from combined oral and nasopharyngeal swab for donation consideration.

2.4 | Demographic data and laboratory parameters

We collected demographic data, symptoms, and clinical signs from the medical records. Laboratory tests were conducted for serum proteins, complete blood count, transfusion-transmitted infections (hepatitis B virus, hepatitis C virus, HIV, malaria, and syphilis), blood grouping, and immunoglobulin G antibody against SARS-CoV-2.

2.5 | Analysis of plasma analytes using bead assay

The concentrations of 21 plasma cytokines, chemokine and growth factors such as interleukin (IL)-1β, IL-2, IL-18, IL-10, interferon-γ (IFN-γ), IL-6, transforming growth factor beta-1, macrophage migration inhibitory factor (MIF), macrophage inflammatory protein (MIP)-1α, MIP-1β, MIP-3α, ITAC, monocyte chemotactic protein-1 (MCP-1), Fractalkine, ENA78, IP-10, M-CSF, Leptin, vascular endothelial growth factor (VEGF)-A, matrix metalloproteinase 12 (MMP12) and E-selectin were determined in 25–30 µl of plasma in all three groups using multiplexed procataplex cytokine bead assay (Thermo Fisher Scientific) following the complete details on Lumimex xponent 3.1TM Rev.2 (Luminex Corporation). A standard curve was drawn using the standards provided in the kits. Values in samples were determined corresponding to the standard curve drawn. The lower limits of detection for each cytokine is given in the Table S1.

2.6 | Multiparametric whole blood immunophenotyping

Monocytes, T-cells, B cells, and Tregs were characterized in whole blood. A total of 100 µl of whole blood sample was stored in 700 µl of FACS Lysing solution (BD Pharmingen) and was stored in −80°C for further use. Using specific antibodies against surface and intracellular markers labeled with different fluorochromes, blood mononuclear cells were characterized.

All samples were processed on a single day in one batch to avoid any batch-to-batch processing variation. FACS Lysed samples were thawed in 37°C water bath for a minute and immediately centrifuged and washed twice with 1X phosphate buffered saline (PBS) containing 0.5% bovine serum albumin with 0.1% Sodium Azide at 400 g for 3 min at the room temperature. After two washes, the cell pellets were stained for surface expressing markers by incubating with appropriate cell-specific antibodies for 30 min at room temperature in the dark. After incubation, the cells were washed and spun at 400g for 3 min to discard the supernatant. The collected pellets were permeabilized with 200 µl FACS permeabilization solution (BD Pharmingen) and incubated for 10 min before washing. After centrifugation, the collected cell pellets were further incubated for 30 min with specific antibodies for intracellular expression of markers. Antibodies were labeled with different fluorochromes and used for detection of B cells; anti-CD3, CD14, CD56, CD19, CD27, CD21, IgD, CD40, CD38, CD274, CD185, CD268, BAFFR, and APRIL, monocytes; anti-CD3, CD56, CD19, CD14, CD16, HLA-DR, CD11b, CD11c, CCR2, CX3CR1, CD80, CD124, CD45, CD163, CD71, CD206, CD123, CD68, and T cells and their subsets; anti-CD3, CD4, CD25, CD27, CCR7, FOXP3, GATA3, CD194, CD278, CD45RA, CD127. Finally, the cell pellets were acquired on FACS ARIA analyzer cum sorter using a minimum of 100,000 events. The data were analyzed by FlowJo software version 10.2 (BD).

2.7 | T cells functionality assay

To investigate the CD4+ and CD8+ T cell functionality in COVID-19 positive patients, their peripheral blood mononuclear cells were cultured in 96-well plates in RPMI media containing 10% fetal bovine serum, with or without phorbol 12-myristate 13-acetate (PMA)/Ionomycin (PMA 2 ng/ml; Ionomycin 1 µg/ml; Merck) and 10 µg/ml lipopolysaccharides (LPS) (Merck) at 37°C on the presence of 5% CO2 for 6 h. After 1 h of incubation, 1 µg/ml brefeldin A (BD Pharmingen) was added to all the wells. After incubation, the cells were surface stained for 25 min with anti-CD3-FITC, anti-CD8-BV421 and anti-CD4-PE/cyanine 5.5 (Cy5) followed by 10 min permeabilization with 100 µl of permeabilizing solution (BD Biosciences) and washed twice with 500 µl 1X cytoperm. The cells were then stained for the intracellular markers
IL-2, IFN-γ, and IL-17 with anti-IL2 APC, anti-IFN-γ PE, anti-IL-17 PE-Cy7 (BD Biosciences and Pharmingen), incubated for another 25 min. Followed by washing with PBS and fixing in 0.1% para formaldehyde, the cells were analyzed on a BD Verse flow cytometer. Data were analyzed using FlowJo.

### 2.8 Plasma proteomic analysis

Total proteins were isolated from the plasma of COVID-19 (n = 15) and convalescent plasma donors (n = 14) and were subjected to mass spectrometry analysis. In brief, total protein was extracted using radio-immunoprecipitation assay (Thermo Fisher Scientific™) as per the instructions recommended by the manufacturer. The extracted proteins were subjected to albumin depletion using ÄKTA pure (Cytiva). Proteins were then precipitated with 100% methanol overnight at −20°C, dissolved in 50 mM ammonium bicarbonate and reduced by dithiothreitol (DTT) for 40 min at 56°C. Proteins were then alkylated by 20 mM iodoacetamide (IAA) for 40 min at room temperature in the dark. The 20 μg of protein samples were then kept for overnight digestion with 1 μg sequencing grade trypsin (Promega) at 37°C. The reaction was stopped by acidifying the peptides using 0.1% formic acid followed by desalted on reversed-phase C18 (Thermo Fisher Scientific). The peptides were then eluted using 50 µl of 60% acetonitrile in 0.1% formic acid and concentrated in a speed vac machine. The peptides were finally acidified with 2% acetonitrile, 0.1% trifluoroacetic acid in 0.1% formic acid. The samples were analyzed by nano-LC-MS/MS coupled to Q-exactive TM plus mass spectrometer (Thermo Fisher Scientific) using software version 10.

### 2.9 Pathway enrichment and immune cell abundance prediction

Differentially expressed proteins (DEPs) were identified followed by the statistical analysis in metaboanalyst. The same web tool was used for performing a classical univariate receiver operating characteristic (ROC) curve and random forest analysis. The DEPs were annotated for Gene Ontology (GO) (Biological Processes) classification using GO database and predicted for hallmark gene sets using Gene Set Enrichment Analysis (GSEA). The abundance of immune cells was predicted using ImmuCellAI. The correlation network of upregulated proteins in COVID-19 patients drew by Immune-Navigator using Edge correlation threshold 0.41 and Significance correlation threshold 0.49.

### 3 RESULTS

#### 3.1 Plasma profile of COVID-19 patients and recovered patients (COPLA donors)

The recruited samples included healthy individuals, COVID-19 patients, and COPLA donors; patients who recovered and donated their convalescent plasma. The plasma and serum samples of the groups were subjected to RT-PCR, Cytokine Bead Array, and proteomics analysis (Figure 1A). The COVID-19 RT-PCR positive patients had a moderate disease with a high respiratory rate (34.47 ± 2.5), low O₂ saturation (85 ± 4.03), low baseline PaO₂/FiO₂ ratio (162.92 ± 13.77), and X-ray changes. Recovered patients who were considered for convalescent plasma donation had a history of mild infection, were RT-PCR negative and at least 14 days passed from their recovery. The mean age, gender, and BMI were comparable between the groups (Table 1).

Principal component analysis revealed a differential level of serum analytes in the serum of the groups (Figure 1B). CX3CL1, CXCL10, MIP1b, VEGF-A, IL-6, MIP1a, Leptin, CCL2, and MIF were significantly increased in COVID-19 positive patients compared to the COPLA donors and healthy subjects. These analytes in the COPLA donors were decreased after 15–21 days of recovery. In addition, a downregulated level of IL-1β, E-selectin, CXCL11, IFN-γ, MIP3a, MMP12, CXCL5, IL-2, and M-CSF was found in the COVID-19 positive patients (Figure 1C). A significant increase in the level of CCL2, CXCL11, MIP3a, E-selectin, VEGF-A, CXCL10, Leptin, MIP1b, IL-10, IL-6, and CXCL1 were detected in the non-survivors compared to the survivors (Figure 1D). Furthermore, the correlation analysis showed that few serum analytes were significantly correlated with the clinical parameters in the COVID-19 patients. An increase in IL-6, MIP1b, and Leptin and CXCL1 (Fratalkine) was significantly correlated with the enhanced FiO₂ concentration and sequential organ failure assessment (SOFA) score (Figure 1E).

Additionally, the serum proteins of COVID-19 patients and COPLA donors were analyzed by LC-MS/MS (Figure 1F).
Out of 1291 identified proteins (Table S1), 100 proteins were upregulated and 128 were significantly downregulated in COVID-19 patients compared to the COPLA donors (Figure 1G). Among the upregulated proteins, 19 proteins were previously shown to be associated with the SARS-CoV-2 infection (Figure S1C). Performing the classical univariate ROC curve analyses (Figure S1D) and the random forest analysis (Figure 1G) showed that SAA1 (Serum amyloid A1), SERPING1 (Plasma protease C1 inhibitor), and SERPING3 were potential markers associated with the SARS-CoV-2 infection. Furthermore, the GO analysis of DEPs showed that expression level of cytokine production associated (GO:0001816) proteins like SAA1, C3, PARK7, SRGN, F2, and CRP was enhanced more than 10-fold in COVID-19 patients (Figure 1H).

3.2 | Increased CXCR3+ve and CCR2+ve monocytes in COVID-19 positive patients and COPLA donors

The whole blood was analyzed by flow cytometry to characterize their immune profile. The gating strategies of the monocytes is given in supplementary material.
The total circulating monocytes were increased in the moderate patients and the recovered COPLA donors compared to the healthy controls (Figure 2A). Further analysis showed that there was no significant change in the number of classical monocytes (CD14$^+$CD16$^-$) in the COVID-19 patients compared to healthy controls; however, an increase in the intermediate (CD14$^+$CD16$^+$) and nonclassical (CD14$^+$CD16$^{++}$) subsets were observed (Figure 2A,B). Despite no change in the number of classical monocytes, the dual expression of HLA-DR/CCR2 and HLA-DR/CX3CR1 was increased in the COVID-19 patients. However, the CCR2 expression was reduced in the intermediate subset in COVID-19 patients.

In the COPLA donors, we observed that the classical monocyte compartment was significantly increased with no change in HLA-DR but with sustained expression of CX3CR1 (Figure 2A,B). Furthermore, the expression of HLA DR$^+$IL4Ra$^+$ was significantly more in COPLA donors (Figure 2A). We further identified that in the COVID-19 patients, an increase in the total monocytes was significantly correlated with the increase in the BMI and RRs. However, a decreased CCR2 expression was correlated with the higher RR in COVID-19 patients, the increased HLA-DR on intermediate and nonclassical monocytes and IL4RA expression was correlated with increased age, FiO$_2$ and PaO$_2$/FiO$_2$ levels (Figure 2C).

### 3.3 Increased central memory T cells in COVID-19 patients and COPLA donors

In patients, the CD3$^+$ T cell compartment was not significantly different from the healthy subjects; however, the ratio of CD4$^+$/CD8$^+$ T cells was skewed in patients more towards CD4$^+$ T cells (Figure 3A). However, the correlation network analysis of upregulated proteins in serum revealed a stronger correlation of expression in CD8$^+$ cells compared to CD4$^+$ cells in COVID-19 patients (Figure S4A).

We further compartmentalized T cells, based on CD45RA, CCR7, and CD27 markers expression into naïve, effector, central memory and effector memory T cells. It was observed that in the COVID-19 patients, CD4$^+$ naïve cells were reduced but the central memory T cells were increased. However, in the CD8$^+$ T cell compartment all naïve, effector, central, and effector memory subsets were increased compared to the healthy samples. Further, in COPLA donors we did not observe any change in CD4$^+$/CD8$^+$ T cells compared to the healthy controls; however, they still had a greater expression of effector and central memory, but reduced effector memory compartment of CD8$^+$ T cells (Figure 3B,C). Besides, the proteomics analysis showed that in the COVID-19 patients the upregulated proteins are more associated with the immune effector process (GO:0002697 and GO:0002252) than the downregulated proteins (Figure 3A,B). Further, the presence of...
upregulated CORO1A (2.3-fold), VCAM1 (1.6-fold), FANCA (73.8-fold) and PRDX2 (4.2-fold) COVID-19 patients serum indicated the increased potential T cells proliferation and differentiation (Figure 3D). Immune cell abundance analysis also predicted a more abundance for central memory and exhausted cells in the patients compared to the COPLA donors (Figure 3E and Figure S4B).

In the COVID-19 patients, the effector, effector memory and central memory CD8+ T cells were negatively correlated with the increase in BMI and platelets count (Figure 3D). We
have also observed that the increased effector CD8+ T cells but not CD4+ T cells in the COVID-19 patients could secrete IFN-γ, IL-17 and IL-2 upon LPS stimulation in vitro. LPS stimulated CD4+ and CD8+ T cells were less polyfunctional in the moderate COVID-19 patients (Figure 4). Accordingly, GSEA analysis of upregulated proteins in the serum of COVID-19 patients showed a high association with the hallmark gene sets for IFN-γ response, IL2-STAT5 signaling and complement (Figure S4C).

3.4 Downregulation of APRIL and BAFR in B cells

A reduction in the total B cells was observed in the COVID-19 patients; however, it was not significantly less than the healthy subjects (Figure 5A). However, the activated B cells were decreased with a lower expression of PDL1 and CD40. Indeed, it was observed that BAFR were significantly reduced in the patients, while the APRIL expressing B cells were significantly reduced in both patients and COPLA donors (Figure 5B). The T follicular helper cells were significantly enhanced in both groups (Figure 5C). In addition, the proteomics analysis showed that among DEPs, 16 proteins that were associated with B cell-mediated immunity (GO:0019724), were downregulated in the serum of COVID-19 patients (Figure 5D). The correlation analysis also revealed that the decreased memory B cells, APRIL and BAFFR expression was negatively correlated with the SOFA score and age of the COVID-19 patients (Figure 5E).

4 DISCUSSION

Analysis of plasma analytes using the cytokine bead assay revealed the involvement of inflammatory monocytes by raising the levels of MIPs, MIF, and CCL2 (MCP-1) in the COVID-19 patients compared to the healthy controls and COPLA donors. Indeed, most of the proinflammatory cytokines such as IL-2, IL-1b, IFN-γ, were expressed similar or lower than the range in healthy controls. Only four patients who did not survive for a week had marginally increased IL-6 levels along with MIPs and MIF. This analysis suggests that other than reported IL-6 and TNF-α, other proinflammatory cytokine storms also do play a role in the severity of COVID-19. Earlier findings also showed high levels of IP-10, MCP-1, MIP-1A, in most of the patients with moderate COVID-19.19 It was observed that instead of an increase in the typical proinflammatory cytokine storm, dynamic immune responses of COVID-19 patients exhibited the role of IL-1 signaling in moderate cases.20 We have also observed that IL-6 levels were significantly correlated with FiO2. Furthermore, COVID-19 were more moderate in the elderly and subjects with comorbidities but also
FIGURE 5  Circulating B cells, their subsets and TFH cells. (A) The percentage of circulating CD19+ B cells and the expression of PDL1, CD40, (B) BAFFR, and APRIL on CD19+ cells, and also (C) the frequency of TFH cells was determined by flow cytometry analysis. (D) The DEPs associated with the B cell‐mediated immunity were mostly downregulated in the serum of COVID-19 patients. (E) The decreased percentage of B cells and expression of APRIL and BAFFR were correlated with the increased SOFA score and age in the moderate COVID-19 patients. r is representing the correlation coefficient. Error short bars show the mean ± SEM. p < .05 was considered significant. APRIL, A proliferation‐inducing ligand; BAFFR, B‐cell activating factor receptor; COVID-19, coronavirus disease 2019; DEP, differentially expressed protein; TFH, T follicular helper.
having the scope of blunted immunity in the elderly may reflect hypo responsiveness for cytokine storm.

The proteomics analysis highlighted the role of SAA1 and SERPING1 in the COVID-19 patients. SAA1 is one of the most important biomarkers in acute inflammation. Enhanced SAA1 level is correlated with the increased immune infiltrating cells. Besides, it has been shown that SAA1 may serve as a biomarker of poor prognosis for COVID-19 as the patients with higher initial SAA levels were shown to be more likely to have poor CT imaging. Besides, the increased level of SERPING1 which transcriptionally regulated by IFN-γ was shown to be correlated with COVID-19. It was suggested that as SERPING1 works as in a negative feedback loop to control contact and complement system activation, the enhanced level of SERPING1 is an attempt by the host to constrain inappropriate complement activation.

SARS-CoV-2 may primarily infect monocyte and CD14+ subsets with higher expressions of CCR2 and CX3CR1 which may differentiate and migrate from the periphery to the target sites as macrophages during infection. Monocytes with higher expression of CCR2 are also considered as senescent monocytes causing inflammatory disease in the elderly due to their shortened telomeres. Although convalescent plasma therapy significantly reduced the RR, improved O2 saturation, and improved the PaO2/FiO2 ratio in COVID-19 patients; COPLA donors had no significant decline in monocyte activation and differentiation. This suggests that patients who have recovered and considered for COPLA donations still have compromised immunity with sustained expression of inflammatory monocytes and activated T cells. The effects of these inflammatory cytokines should be observed postinfusion into plasma recipients suffering from COVID-19, and are already in a hyper-inflammatory state. Increased plasma MCP-1 and CCR2 on monocytes in COVID-19 patients and COPLA donors strongly suggest that SARS-CoV-2 specifically target this population and is responsible for keeping a sustained inflammatory environment even after clearance of this virus.

In viral infections, although the functional role of CD8+ T cell is crucial still needs to be well-modulated in order not to cause moderate pathology. But T cell responses especially CD8+ T cells in SARS-CoV-2 infection showed greater magnitude in the secretion of IFN-γ and TNF-α than CD4+ T cells. The early rise of CD8+ T cells and IL-4, IL-5, and IL-10 producing TH2 cells were detected more in patients with mortality. The present study revealed a bigger pool of CD8+ T cells secreting IL-17, IFN-γ, and IL-2 than CD4+ T cells; however, lower than healthy subjects. Although, the protective or destructive role of Th17 in human coronavirus infection remains unanswered. Indeed, in the convalescent phase, we observed Th1 type helper T cells, but still, there was a low expression of activation markers on B cells. APRIL and BAFFR expression regulate the compartment of translational B cells to mature B cells. Recently, APRIL and BAFF expression was also observed more in IL-10 producing regulatory B cell compartment. Bregs acts as copartners with Tregs in inhibiting excessive inflammation. Although, Bregs skew T cells expression and also are functional in suppressing Th1 and Th17 differentiation, in our study, we have observed low expression of BAFFR and APRIL on B cells suggesting that B cells were not actively proliferating, although in COPLA donors their expression was enhanced compared to the COVID patients, still it was under-expressed than healthy.

In conclusion, SARS CoV-2 infection induces pathogenesis by monocyte trafficking and differentiation via CCR2 and CX3CR1, MIPs, and MIFs and with reducing APRIL and BAFFR expression, and there was sustained expression of these markers even after 3 weeks of recovery in COPLA donors.

ACKNOWLEDGMENTS

We thank our technician, Mr. Dileep, at MCM for the storage and initial processing of samples. This study was supported by the intramural funding of the corresponding author.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

Meenu Bajpai, Suresh Kumar, Shiv K Sarin, and Ashish Maheshwari recruited, characterized, and conducted the clinical investigations of all patients and COPLA donors. Nirupama Trehanpati conceptualized the study, Ravinder Singh and Nirupama Trehanpati processed all samples in the laboratory. Hamed Hemati performed all proteomics and bioinformatics analysis. Jayesh Kumar Sevak and Islam, Mojahidul conducted the cytokine bead assay. Pushpa Yadav and Sonal Agrawal, analyzed cytokine bead assay and flow cytometry data along with Nirupama Trehanpati. NTP and Hamed Hemati wrote and finalized the manuscript. Shiv K Sarin provided critical inputs.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICS STATEMENT

The study was approved by the review board and the Ethical Committee of the Institution of Liver and Biliary Sciences, New Delhi, India (No.F.37/(1)/9/ILBS/DOA/2020/20217/
Informed consent was obtained from each patient or their legal guardians. Each patient was followed till discharge from the hospital. All investigations were performed in accordance with the declaration of Helsinki.

**REFERENCES**

1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The lancet*. 2020;395(10229):1054-1062.

2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The lancet*. 2020;395(10223):507-513.

3. Jiang X-L, Zhang X-L, Zhao X-N, et al. Transmission potential of asymptomatic and paucisymptomatic severe acute respiratory syndrome coronavirus 2 infections: a 3-family cluster study in China. *J Infect Dis*. 2020;221(12):1948-1952.

4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The lancet*. 2020;395(10223):497-506.

5. Zhang D, Guo R, Lei L, et al. Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. *J Leukoc Biol*. 2021;109(1):13-22.

6. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis*. 2020;71(15):762-768.

7. Fung S-Y, Yuen K-S, Ye Z-W, Chan C-P, Jin D-Y. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. *Emerg Microbes Infect*. 2020;9(1):558-570.

8. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. *N Engl J Med*. 2020;382:1787-1799.

9. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. *N Engl J Med*. 2020;382(24):2327-2336.

10. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. *JAMA*. 2020;323(16):1582-1589.

11. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. *Lancet Infect Dis*. 2020;20(4):398-400.

12. Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. *Chest*. 2020;158(1):e9-e13.

13. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci USA*. 2020;117(17):9490-9496.

14. Pang Z, Chong J, Li S, Xia J. MetaboAnalystR 3.0: Toward an optimized workflow for global metabolomics. *Metabolites*. 2020;10(5):186.

15. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. *Nature Genet*. 2000;25(1):25-29.

16. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA*. 2005;102(43):15545-15550.

17. Miao Y-R, Zhang Q, Lei Q, et al. ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. *Adv Sci*. 2020;7(7):1902880.

18. Vandenbon A, Dinh VH, Mikami N, et al. Immuno-navigator, a batch-corrected coexpression database, reveals cell type-specific gene networks in the immune system. *Proc Natl Acad Sci USA*. 2016;113(17):E2393-E2402.

19. Prompetchara E, Kelloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. *Asian Pac J Allergy Immunol*. 2020;38(1):1-9.

20. Ong EZ, Chan YFZ, Leong WY, et al. A dynamic immune response shapes COVID-19 progression. *Cell Host Microbe*. 2020;27(6):570-582.

21. Zhang W, Kong H-F, Gao X-D, et al. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma. *World J Gastroenterol*. 2020;26(35):5287-5301.

22. Li H, Xiang X, Ren H, et al. Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis. *J Infect*. 2020;80(6):646-655.

23. Hausburg MA, Banton KL, Roshon M, Bar-Or D. Clinically distinct COVID-19 cases share notably similar immune response progression: a follow-up analysis. *Helyton*. 2021;7(1):e05877.

24. Ziegler CD, Carracedo J. Senescent CD14+ CD16+ monocytes exhibit proinflammatory and proatherosclerotic activity. *The Journal of Immunology*. 2011;186(3):1809-1815.

25. Merino A, Buendia P, Martin R, et al. Sustained expression of monocytes and dendritic cells in blood. *Chest*. 2020;158(1):e9-e13.

26. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. *Nature Genet*. 2000;25(1):25-29.

**SUPPORTING INFORMATION**

Additional Supporting Information may be found online in the supporting information tab for this article.

**How to cite this article:** Singh R, Hemati H, Bajpai M, et al. Sustained expression of inflammatory monocytes and activated T cells in COVID-19 patients and recovered convalescent plasma donors. *Immun Inflamm Dis*. 2021;9:1279–1290. https://doi.org/10.1002/iid3.476